Jeremiah Bearss
Vice President - Clinical Development Biolexis Therapeutics
Dr. Jeremiah Bearss is the Vice President of Clinical Development at Biolexis Therapeutics, where he leads the design and execution of early-phase clinical trials for innovative small-molecule therapies targeting metabolic indications. He completed his Internal Medicine residency at Mayo Clinic Hospital in Phoenix, AZ, earning multiple departmental awards for excellence in patient care.
Dr. Bearss holds an MD/PhD from the University of Arizona, where his research in oncogenic signaling and P-body dynamics contributed to the development of novel PIM kinase inhibitors. He brings extensive translational research experience from both academic and biotech settings, including previous roles at Montigen and Tolero Pharmaceuticals.
Seminars
- Advancing clinical development, sharing Phase 1 safety and tolerability findings, and the transition into longer-duration Phase 1b studies evaluating ongoing efficacy
- Exploring a differentiated oral GLP-1 highlighting new preclinical and clinical insights into a novel allosteric GLP-1 mechanism, including its distinctive molecular profile and encouraging GI tolerability, with no meaningful nausea or vomiting observed to date
- Preserving muscle beyond weight loss Exploring the AMPK activator program in combination with GLP-1 therapy and its potential to support muscle preservation, alongside the next development milestones for both programs
